The tropism-ablating triple mutation completely blocked all native cell entry pathways of 77 
(NVRGDLQVLAQKVART) was edited to conform with the A20 peptide sequence used in this 160 study (NAVPNLRGDLQVLAQKVART), docked to the Ad5 fiber knob structure in the HI loop 161 and the KO1 mutation added using WinCoot (36) and PyMol 2.0 (37). The crude Ad5 NULL -162 A20 structure was aligned with the existing 5NEM structure and the complex energy 163 minimised using the YASARA algorithm (38). Binding energy calculations were performed 164 using PISA (39), and surface charge calculated using APBS tool in PyMol 2.0 (37). 165 αvβ6-high/CAR+ SKOV3-β6 cell line was generated in-house by retroviral transfection 166 of SKOV3 cells [that natively express the αv subunit (40)] with integrin beta6 pBABE puro 167 plasmid to express the 6 subunit. Primary EOC cells from ascites were obtained throughof anti Ad5 antibodies in ovarian ascites and serum was determined by ELISA as previously 174 reported (41). Antigen specificity of the antibodies was assessed by Western blot. 175
Transduction efficiency was assessed by standard luciferase assays, described previously 176 (30, 31). Animal experiments were approved by Institutional Care and Use Committee 177 (IACUC) and performed at Mayo Clinic, Rochester, MN, USA. Animals were age and sex-178 matched. Animal handling and injections were performed by a veterinary technologist. In 179 vivo experiments are further described in detail in Supplementary Methods. 180
Statistical analyses 181
Figures and statistical analyses were generated using GraphPad Prism v6.03. In vitro 182
and ex vivo assays were analysed by two-tailed unpaired t-tests or one-way ANOVA with 183 
RESULTS

189
We generated and produced to very high viral titres replication-defective and oncolytic 190 variants of a novel Ad5 NULL -A20 vector (Fig. 1A) with three de-targeting mutations and an 191 A20 peptide insertion that re-targets the vector to αvβ6 integrin-expressing cells (Fig. 1B) . 192
Additionally, we generated replication deficient and oncolytic versions of Ad5.A20, which 193 harbours the αvβ6 targeting-peptide A20 insertion, in the absence of any de-targeting 194 modification. The multiple genetic manipulations did not have a significant impact on viral(dark blue) and the native knob structure (cyan) against the approximated charge surface of 200 the ανβ6 (red is negative, blue is positive, Fig. 1D ). The ανβ6 has mostly negative surface 201 potential in this region (1D), complementary to the predominantly positive charge of the 202 Ad5 NULL -A20 interface (Suppl. Fig. I A) . The adjacent CD loop of the native Ad5 fiber knob 203 contributes two polar residue interactions from Lys-442 and Gly-443 (1D), binding to an 204 additional three αν residues (Suppl. Fig. I B) . The binding energy of the ανβ6-Ad5 NULL -A20 205 fiber knob complex is calculated to be -24.3 Kcalmol Fig. 2B; left panel) . Conversely, addition of human FX in culture medium had no effect on 215 the transduction efficiency of the FX binding-ablated Ad5.HVR7 control vector in these cells 216 ( Fig. 2B; right panel) . Furthermore, the enhanced transduction seen for Ad5 was reversed by 217 the addition of a 3:1 molar excess of Gla-domain interacting protein, anticoagulant X-bp, that 218 binds and inactivates FX in the medium (19) (Fig. 2B, left panel) . On the contrary, FX 219 depletion did not affect the transduction of Ad5.HVR7 vector (Fig. 2B, right panel) . 220
We confirmed αvβ6 integrin as the primary entry receptor for the triply de-targeted, 221 integrin re-targeted Ad5 NULL -A20 vector (Fig. 3) . Ad5 NULL -A20 transduced αvβ6+/CAR-BT-20derived EOC004 cells (αvβ6+/CAR-) at 69-fold increased efficiency ( Fig. 3B ; p=0.0090) 224 relative to Ad5. Competition assays using a function-blocking anti-αvβ6 antibody (10D5) 225 significantly inhibited cell transduction by Ad5 NULL -A20 vector in SKOV3-β6 cells 226 (αvβ6+/CAR+) ( Fig. 3C ; p=0.0010), confirming the vector's selectivity for αvβ6 integrin 227
We next evaluated the ability of the Ad5 NULL -A20 vector to retain its infectivity in the 228 highly neutralising environment presented by ovarian ascites. To this end, freshly isolated 229 clinical OAS samples from twenty ovarian cancer patients were screened for the presence of whilst the most abundant capsid protein -hexon -was recognised only at very low levels in 237
Western blot using denatured whole viral particles (Fig. 4B) . The neutralising effect of 238 OAS001 on transduction efficiency of Ad5 NULL -A20 was assessed in αvβ6+/CAR-EOC004 239 primary cells. Ad5 NULL -A20 showed up to 902-fold higher transduction efficiency in primary 240 human EOC cultures relative to Ad5 at OAS concentrations of 2.5, 5 and 10%, whilst Ad5 241 was not capable of transducing these cells at detectable levels (Fig. 4C) . 242
We next evaluated biodistribution of virus infection in immunocompetent, non-tumour-243 bearing mice. Mice were injected intravenously with replication-defective vectors to assess in 244 vivo tropism (Fig. 5A) , in particular the effect of the three de-targeting mutations on 245 biodistribution of virus infection. As expected and as previously documented, the Ad5 vector 246
showed intense localisation in the area of liver and spleen, while luminescence by the 247 Ad5 NULL -A20 vector was completely undetectable at the 72-h time-point (Fig. 5B) . Animals 248 inoculated with Ad5 vector had significantly higher whole-body luminescence than the 249 control animals (p<0.0001) or the Ad5 NULL -A20 vector (p<0.0001) (Fig. 5C ). The liver, spleen,11 lungs, ovaries and heart were resected post-mortem and quantified for ex vivo luminescence 251 (for luminescence heat-maps, see Suppl. Fig. II A-C) . The livers of Ad5-challenged animals 252 emitted significantly more luminescence than the PBS control or Ad5 NULL -A20 groups (both 253 p<0.0001) (Fig. 5D) . Similarly, Ad5 NULL -A20 had significantly decreased transgene 254 expression in the spleen, lungs, ovaries and heart, relative to Ad5 ( Fig. 5E-H Confirmation that the modifications in Ad5 NULL -A20 resulted in reduced sequestration of 257 virus in multiple normal tissues was performed via quantitation of viral load by qPCR. 258
Genome copy number of the Ad5 NULL -A20 vector was 10 million times lower in the liver 259 relative to the Ad5 ( Fig. 6A ; p<0.0001). Similarly, Ad5 NULL -A20 genome copy number was 260 over 700-fold lower in the spleen compared to Ad5 ( Fig. 6B ; p<0.0001). In addition, the 261 Ad5 NULL -A20 vector showed improved off-target profiles in all organs relative to Ad5, with 262 viral load 10 5 , 10 4 and 10 3 lower in the lungs, heart and ovaries, respectively ( Fig. 6C- 
E). 263
Successful de-targeting of the liver being due to our genetic modifications of Ad5 is 264 supported by immunohistochemical staining of liver sections, which showed high expression 265 levels of CAR, whilst αvβ6 was undetectable (Suppl. Fig. III A) . Confirmation of the de-266 targeting effects of genetic modifications in Ad5 NULL -A20 is provided by the observation that 267 liver sections from mice showed positive staining for Ad capsid proteins in the Ad5 group, 268
but not in livers of mice that had been challenged with the Ad5 NULL -A20 vector (Suppl. Fig. III (Fig.  282   7B) . This distribution was maintained, but at lower intensity, until 5 days later, day 21 (Fig.  283   7B) . In contrast, the oncolytic Ad5 NULL -A20 vector however, showed selective tumour 284 localisation, with significantly reduced overall luminescence relative to Ad5, consistent with 285 successful de-targeting of non-tumour tissues. The distribution of infection mediated by the 286 oncolytic Ad5.A20 vector was intermediate between the Ad5 and Ad5 NULL -A20. Quantitation 287 of total body luminescence showed uptake of the Ad5 NULL -A20 vector to be significantly lower 288 than Ad5 both on day 16 (Fig 7C; p<0 .05 and <0.01, respectively) and on day 21 ( Fig. 7D;  289 p<0.0001), while there was no statistically significant difference in the uptake of Ad5.A20 as 290 compared to Ad5. 291 Anti-tumour activity was observed for oncolytic Ad5, oncolytic Ad5.A20 and oncolytic 292
Ad5 NULL -A20 in the SKOV3 xenograft model (Fig 7E) . Consistent with an enhanced tumour-293 selective effect of Ad5 NULL -A20, all mice treated with Ad5 NULL -A20 were still alive and tumour-294 free at the final time-point of 101 days, while animals treated with either Ad5 or Ad5.A20 295 almost identical (and statistically not significantly different) survival curves with median 296 survival of around 60 days. 297 298 vector, Ad5 NULL -A20 which is ablated for all known native tropisms and re-targeted to an 301 over-expressed, prognostic cancer marker -αvβ6 integrin (43). Integrin αvβ6 is a promising 302 target for therapeutic cancer applications due to its over-expression in aggressively 303 transformed cancers (4). A20 peptide is a feasible tool for a variety of clinical applications, 304 and has been used for imaging diagnostics in an αvβ6+ pancreatic tumour model (44) In silico evaluation of the Ad5 NULL -A20 interface with ανβ6 by homology modelling (Fig.  314 1; Suppl. Fig. I ) predicts the Ad5 NULL -A20 fiber knob domain to form a low entropy interface 315 with ανβ6. A20 possesses the putative RGD integrin interacting motif (48) but specificity to 316 the β6 subunit is derived from the helical motif C-terminal of RGD. It is further stabilised by 317 electrostatic interactions across the interface and polar bonds between αν and the Ad5 CD 318 loop. Each fiber trimer possesses three copies of the A20 peptide, with 12 trimeric fibers per 319 adenovirus capsid, thus Ad5 NULL -A20 possesses 36 potential ανβ6 interaction sites per viral 320 particle. While not all these sites will be utilised in a single cellular interaction it is extremely 321 likely that the virus benefits from a potent avidity effect when interacting with a cell 322 possessing multiple ανβ6 copies. 323
In the present study, we presented the Ad5 NULL -A20 as a highly selective vectorαvβ6+ cells, in vitro and ex vivo (Fig. 3) . Although the efficacy-limiting interactions that occur 327 in systemic delivery of adenoviral vectors can, theoretically, be bypassed by intra-cavity 328 administration of the vector via the i.p. route, in practice this approach presents challenges 329 since wild-type Ad5 is sequestered by pre-existing anti-Ad5 immunity in the form of 330 neutralising antibodies (nAbs) in ascitic fluid (41, 49, 50). We therefore assessed the 331 transduction efficiency of Ad5 NULL -A20 in the presence of freshly-isolated clinical OAS from 332 ovarian cancer patients with confirmed high levels of anti-Ad5 nAbs (Fig. 4A) . Unlike the Ad5 333 vector, Ad5 NULL -A20 retained its ability to transduce αvβ6+ cells, even at relatively high OAS 334 concentrations (Fig. 4C) . 335
Clinical efficacy of therapeutic Ad5 vectors with unmodified capsids is also significantly 336
limited by off-target tissue sequestration, particularly in the liver. We demonstrate that 337
Ad5 NULL -A20 significantly altered the biodistribution of the Ad5 vector in vivo by reducing the 338 sequestration in remarkable magnitudes. In tumour-free mice, replication-deficient Ad5 NULL -339 A20 demonstrated significantly reduced viral transgene expression the liver, spleen and 340 lungs compared to the parental Ad5 (Fig. 5) , and lower viral genome copy number in all off-341 target organs relative to the Ad5 vector (Fig. 6) . 342
To test efficacy of an oncolytic form of our de-targeted/re-targeted Ad5 NULL -A20 vector, 343 we established an orthotopic i.p. xenograft model of human EOC SKOV3 in 344 immunocompromised mice. The more localised bio-distribution of virally-encoded transgene 345 expression of oncolytic Ad5 NULL -A20 following intraperitoneal administration was consistent 346 with reduced off-target sequestration and/or tumour-selective virus uptake (Fig. 7B-E) . This 347 was supported by the superior survival of animals treated with Ad5 NULL -A20 relative to Ad5 in 348 a SKOV3 xenograft model (Fig. 7E) , although extended survival (compared to unmodifiedand selective retargeting mechanism to tumour-associated ligands, such as the αvβ6: A20 353 receptor: ligand interaction. This observation likely explains previous studies (51, 52) which 354 described no improved efficacy (compared to oncolytic Ad5) of virotherapies targeted to 355 αvβ6 integrin, since the vectors used in those studies lacked modifications in at least two of 356 the three native infectious pathways (the hexon: FX and penton base: αvβ3/5 interactions). 357
Additional studies will be needed to fully evaluate v6+ cancer re-targeting in vivo, as well 358 as to dissect the fate in tissues and immunological responses to the Ad5 NULL -A20 vector. 
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